Is ACET or ALLR more profitable?

Adicet Bio's return on equity of -74.90% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adicet Bio N/A -74.90% -60.87% Allarity Therapeutics N/A -152.77% -46.50%

Is GANX or ALLR more profitable?

Allarity Therapeutics' return on equity of -152.77% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Allarity Therapeutics N/A -152.77% -46.50%

Which has preferable earnings and valuation, ALLR or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allarity Therapeutics $320K 70.10 -$11.23M -$0.78 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is ALLR or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% OKYO Pharma N/A N/A N/A

Do analysts prefer TELO or ALLR?

Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 626.95%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TELO or ALLR more profitable?

Telomir Pharmaceuticals' return on equity of -102.70% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Allarity Therapeutics N/A -152.77% -46.50%

Allarity Therapeutics (ALLR) Competitors

$1.41 +0.03 (+2.17%)

As of 08/28/2026 04:00 PM Eastern

Compare

ALLR vs. SERA, ACET, GANX, OKYO, and TELO

Should you buy Allarity Therapeutics stock or one of its competitors? Allarity Therapeutics's main competitors and comparable companies include Sera Prognostics (SERA), Adicet Bio (ACET), Gain Therapeutics (GANX), OKYO Pharma (OKYO), and Telomir Pharmaceuticals (TELO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Allarity Therapeutics compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

In the previous week, Sera Prognostics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 2 mentions for Sera Prognostics and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.87 beat Sera Prognostics' score of 0.94 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Positive
Allarity Therapeutics	Very Positive

Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 165.70%. Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 626.95%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allarity Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Sera Prognostics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Allarity Therapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$70K	1,166.56	-$31.93M	-$0.67	N/A
Allarity Therapeutics	$320K	70.10	-$11.23M	-$0.78	N/A

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Sera Prognostics beats Allarity Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Allarity Therapeutics compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Adicet Bio's return on equity of -74.90% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-74.90%	-60.87%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Adicet Bio currently has a consensus price target of $46.80, indicating a potential upside of 416.56%. Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 626.95%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than Adicet Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Adicet Bio had 6 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for Adicet Bio and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.87 beat Adicet Bio's score of 0.52 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adicet Bio	Positive
Allarity Therapeutics	Very Positive

Allarity Therapeutics has higher revenue and earnings than Adicet Bio. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80M	-$11.45	N/A
Allarity Therapeutics	$320K	70.10	-$11.23M	-$0.78	N/A

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 3.4% of Adicet Bio shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adicet Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Summary

Adicet Bio beats Allarity Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Allarity Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Allarity Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,544.86	-$20.16M	-$0.50	N/A
Allarity Therapeutics	$320K	70.10	-$11.23M	-$0.78	N/A

In the previous week, Gain Therapeutics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 2 mentions for Gain Therapeutics and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.87 beat Gain Therapeutics' score of 0.96 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Positive
Allarity Therapeutics	Very Positive

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gain Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 323.73%. Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 626.95%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allarity Therapeutics' return on equity of -152.77% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Summary

Allarity Therapeutics beats Gain Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Allarity Therapeutics compare to OKYO Pharma?

Allarity Therapeutics (NASDAQ:ALLR) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Allarity Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

OKYO Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
OKYO Pharma	N/A	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	70.10	-$11.23M	-$0.78	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Allarity Therapeutics presently has a consensus target price of $10.25, suggesting a potential upside of 626.95%. OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 239.32%. Given Allarity Therapeutics' higher probable upside, research analysts clearly believe Allarity Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, OKYO Pharma had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 2 mentions for OKYO Pharma and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.87 beat OKYO Pharma's score of 1.43 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Very Positive
OKYO Pharma	Positive

Summary

OKYO Pharma beats Allarity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Allarity Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 626.95%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has higher earnings, but lower revenue than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Allarity Therapeutics	$320K	70.10	-$11.23M	-$0.78	N/A

Telomir Pharmaceuticals' return on equity of -102.70% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Allarity Therapeutics	N/A	-152.77%	-46.50%

11.5% of Allarity Therapeutics shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.87 beat Telomir Pharmaceuticals' score of 0.63 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Positive
Allarity Therapeutics	Very Positive

Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

Allarity Therapeutics beats Telomir Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLR vs. The Competition

Export

Metric	Allarity Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.43M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.81	11.62	273.16	25.42
Price / Sales	70.10	1,369.80	630.81	94.42
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.31	16.92	11.08	6.36
Net Income	-$11.23M	-$22.74M	$3.48B	$349.79M
7 Day Performance	-0.70%	-0.31%	0.13%	-0.80%
1 Month Performance	14.63%	9.80%	7.08%	4.13%
1 Year Performance	-8.44%	55.66%	24.67%	15.17%

Allarity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLR Allarity Therapeutics	2.781 of 5 stars	$1.41 +2.2%	$10.25 +627.0%	-8.4%	$22.43M	$320K	N/A	10	Positive News
SERA Sera Prognostics	2.8005 of 5 stars	$2.15 -1.4%	$5.50 +155.8%	-35.9%	$84.82M	$80K	N/A	120
ACET Adicet Bio	3.7705 of 5 stars	$8.83 -1.9%	$46.80 +430.3%	-21.4%	$82.63M	N/A	N/A	90	News Coverage Analyst Downgrade Short Interest Decrease Gap Up
GANX Gain Therapeutics	2.1838 of 5 stars	$1.88 -1.2%	$7.50 +298.5%	-11.1%	$82.31M	$50K	N/A	20
OKYO OKYO Pharma	3.066 of 5 stars	$1.56 +3.7%	$5.67 +264.2%	-28.9%	$81.66M	N/A	N/A	7	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allarity Therapeutics (ALLR) Competitors

ALLR vs. SERA, ACET, GANX, OKYO, and TELO

How does Allarity Therapeutics compare to Sera Prognostics?

Summary

How does Allarity Therapeutics compare to Adicet Bio?

Summary

How does Allarity Therapeutics compare to Gain Therapeutics?

Summary

How does Allarity Therapeutics compare to OKYO Pharma?

Summary

How does Allarity Therapeutics compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allarity Therapeutics (ALLR) Competitors

ALLR vs. SERA, ACET, GANX, OKYO, and TELO

How does Allarity Therapeutics compare to Sera Prognostics?

Does the media prefer SERA or ALLR?

Do analysts rate SERA or ALLR?

Is SERA or ALLR more profitable?

Which has more risk & volatility, SERA or ALLR?

Which has preferable earnings & valuation, SERA or ALLR?

Do insiders and institutionals hold more shares of SERA or ALLR?

Summary

How does Allarity Therapeutics compare to Adicet Bio?

Is ACET or ALLR more profitable?

Do analysts prefer ACET or ALLR?

Does the media refer more to ACET or ALLR?

Which has stronger valuation and earnings, ACET or ALLR?

Do insiders & institutionals hold more shares of ACET or ALLR?

Which has more volatility and risk, ACET or ALLR?

Summary

How does Allarity Therapeutics compare to Gain Therapeutics?

Which has stronger earnings & valuation, GANX or ALLR?

Does the media favor GANX or ALLR?

Do insiders & institutionals hold more shares of GANX or ALLR?

Which has more risk and volatility, GANX or ALLR?

Do analysts rate GANX or ALLR?

Is GANX or ALLR more profitable?

Summary

How does Allarity Therapeutics compare to OKYO Pharma?

Do institutionals and insiders believe in ALLR or OKYO?

Which has more volatility and risk, ALLR or OKYO?

Is ALLR or OKYO more profitable?

Which has preferable earnings and valuation, ALLR or OKYO?

Do analysts rate ALLR or OKYO?

Does the media refer more to ALLR or OKYO?

Summary

How does Allarity Therapeutics compare to Telomir Pharmaceuticals?

Do analysts prefer TELO or ALLR?

Which has stronger earnings & valuation, TELO or ALLR?

Is TELO or ALLR more profitable?

Do institutionals & insiders hold more shares of TELO or ALLR?

Does the media refer more to TELO or ALLR?

Which has more volatility and risk, TELO or ALLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools